C̲̲Z🔸 retweeted
The relentless quest for biomarkers predicting the outcome of immune-checkpoint blockade:
👉in press in Annals of Oncology, plasma proteomics identify Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of resistance annalsofoncology.org/article… @GustaveRoussy @y_loriot
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance annalsofoncology.org/article…
Fascinating paper investigating the gene expression program of mutation associated neoantigen-specific -TIL in cancer patients treated with ICI. Detectable in a majority of patients (Blood and tissue)
Opening the black box of undifferentiated pleomorphic sarcomas authors.elsevier.com/sd/arti…
Identifying DNA Repair gene mutations beyond BRCA may have a strong clinical impact authors.elsevier.com/a/1b3ea…
Molecular profiling results are biased by undersampling. Sequencing of usually discarded tumor material improve the accuracy of molecular data.
Up to 25% of Sarcoma patients have monogenic or polygenic variants in DDR genes. DDR targeting deserves more investigation in this devastating group of diseases.
Presence of tertiary lymphoid structures as a predictive biomarker of immune-checkpoint inhibitors benefit in sarcomas: moving toward personalized immunotherapy for our patients
1st Molecular Tumor Board of the MULTISARC study. Proud of the team who did an amazing work to make this study feasible. Thanks to INSERM and French Sarcoma Group
2018 Annual meeting of the French Sarcoma Group in Montpellier. Friendly atmosphere, productive collaboration.
High rate of DDR genes alterations and occurence of BRAF in frame deletions sensitive to MEK inhibition in pancreatic cancer : moving forward precision medicine
Thousands of people celebrating "the wine" in Bordeaux. Fantastic event but missed opportunity to inform about the risks of an overconsumption.
2
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients nyti.ms/2vsMRXfp an US problem ? In France: not enough drug trials !















